MoonLake Immunotherapeutics (MLTX) Non-Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 25.31% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (down 25.31% YoY), while the FY2025 annual figure was $2.7 million, down 24.84% from the prior year.
• Non-Current Assets was $3.7 million for Q1 2026 at MoonLake Immunotherapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $115.1 million in Q1 2022 to a low of $52679.0 in Q3 2022.
• Historically, Non-Current Assets has averaged $10.3 million across 5 years, with a median of $3.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 99.95% in 2022, then soared 3627.1% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $331969.0 in 2022, then jumped by 3627.1% to $12.4 million in 2023, then plunged by 70.55% to $3.6 million in 2024, then declined by 24.84% to $2.7 million in 2025, then surged by 36.29% to $3.7 million in 2026.
• The last three Non-Current Assets figures came in at $3.7 million (Q1 2026), $2.7 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.